F.) Update from Across the Pond

Liz Darlison, Nurse Consultant
Mesothelioma UK

Liz Darlison trained at Charles Frears School of Nursing in Leicester qualifying in 1986. Since 1992 she has been based within the cardio-respiratory directorate of the University Hospitals of Leicester at the Glenfield Hospital site. Liz was a ward sister/manager in respiratory for several years and in June 2000 she took up the post of Respiratory Nurse Specialist (Lung Cancer). Liz’s interests within lung cancer have always focused on developing the nursing contribution, within the multidisciplinary team, to improve patient and carer experience across the whole cancer pathway. To meet demand locally and nationally Liz developed an interest in Mesothelioma which resulted in the establishment of Mesothelioma UK, the National Macmillan Mesothelioma Resource Centre. Liz is currently a Consultant Nurse leading the development of Mesothelioma UK.


Click here to view the slides for "Update from Across the Pond" by Liz Darlison, Nurse Consultant.

To view the video presentation, please click on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

I.) Present and Future of Mesothelioma Treatment: Surgeon and Researcher Perspective

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

L.) Photodynamic Therapy

M.) Pain Management

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion